Literature DB >> 16139452

Mitochondrial delivery of mastoparan with transferrin liposomes equipped with a pH-sensitive fusogenic peptide for selective cancer therapy.

Yuma Yamada1, Yasuo Shinohara, Tomoyuki Kakudo, Shinji Chaki, Shiroh Futaki, Hiroyuki Kamiya, Hideyoshi Harashima.   

Abstract

Mastoparan (MP), a potent facilitator of mitochondrial permeability transition (PT), could be used as an antitumor agent, if it were encapsulated in a tumor selective delivery system. We recently developed transferrin-modified liposomes (Tf-L) with a pH-sensitive fusogenic peptide (GALA), which delivers an encapsulated fluorescent marker into cytosol efficiently. In this study, we encapsulated MP into Tf-L with GALA for the selective delivery to mitochondria of tumor cells. The MP showed potent PT activity at concentrations above 25 microM in a homogenate of K 562 cells as well as in isolated mitochondria in the presence of phosphate. Tf-L equipped with cholesteryl GALA can release encapsulated sulforhodamine B, while Tf-L failed, as evidenced by confocal laser scanning microscopy. The MP, which was delivered with Tf-L with GALA, released cytochrome c (cyt c) from mitochondria to the cytosol, while free MP released cyt c not only to the cytosol but also extracellulary. These results demonstrate the utility of MP in Tf-L with GALA for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139452     DOI: 10.1016/j.ijpharm.2005.06.009

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

Review 1.  Helminthes and insects: maladies or therapies.

Authors:  Nora L El-Tantawy
Journal:  Parasitol Res       Date:  2014-12-30       Impact factor: 2.289

2.  Novel pH-sensitive polyacetal-based block copolymers for controlled drug delivery.

Authors:  Jin-Ki Kim; Vivek Kumar Garripelli; Ui-Hyeon Jeong; Jeong-Sook Park; Michael A Repka; Seongbong Jo
Journal:  Int J Pharm       Date:  2010-08-27       Impact factor: 5.875

3.  Efficient protection and transfection of small interfering RNA by cationic shell-crosslinked knedel-like nanoparticles.

Authors:  Yuefei Shen; Huafeng Fang; Ke Zhang; Ritu Shrestha; Karen L Wooley; John-Stephen A Taylor
Journal:  Nucleic Acid Ther       Date:  2013-04       Impact factor: 5.486

4.  Pro-necrotic Activity of Cationic Mastoparan Peptides in Human Glioblastoma Multiforme Cells Via Membranolytic Action.

Authors:  Annielle Mendes Brito da Silva; Laíz Costa Silva-Gonçalves; Fernando Augusto Oliveira; Manoel Arcisio-Miranda
Journal:  Mol Neurobiol       Date:  2017-09-30       Impact factor: 5.590

Review 5.  Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: melittin, apamin and mastoparan.

Authors:  Miguel Moreno; Ernest Giralt
Journal:  Toxins (Basel)       Date:  2015-04-01       Impact factor: 4.546

6.  Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson's substantia nigra.

Authors:  Scott Ayton; Peng Lei; Catriona Mclean; Ashley I Bush; David I Finkelstein
Journal:  Signal Transduct Target Ther       Date:  2016-09-02

Review 7.  Bioactive Peptides and Proteins from Wasp Venoms.

Authors:  Lei Luo; Peter Muiruri Kamau; Ren Lai
Journal:  Biomolecules       Date:  2022-03-30

Review 8.  Mastoparans: A Group of Multifunctional α-Helical Peptides With Promising Therapeutic Properties.

Authors:  Carlos José Correia de Santana; Osmindo Rodrigues Pires Júnior; Wagner Fontes; Mário Sérgio Palma; Mariana S Castro
Journal:  Front Mol Biosci       Date:  2022-06-24

Review 9.  Wasp Venom Biochemical Components and Their Potential in Biological Applications and Nanotechnological Interventions.

Authors:  Aida Abd El-Wahed; Nermeen Yosri; Hanem H Sakr; Ming Du; Ahmed F M Algethami; Chao Zhao; Ahmed H Abdelazeem; Haroon Elrasheid Tahir; Saad H D Masry; Mohamed M Abdel-Daim; Syed Ghulam Musharraf; Islam El-Garawani; Guoyin Kai; Yahya Al Naggar; Shaden A M Khalifa; Hesham R El-Seedi
Journal:  Toxins (Basel)       Date:  2021-03-12       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.